Using individual responses in all risk markers significantly improved renal risk prediction (RIDI 30.4%; p<0.01) compared to using only SBP changes. Results were successfully replicated in two independent trials with irbesartan; IDNT and IRMA-2.
Introduction
Intervention in the renin-angiotensin-aldosterone system (RAASi) is a mainstay of renoprotective therapy in diabetic (and non-diabetic) renal disease [1] [2] [3] . Although
RAASi affords renoprotection on a group level, large individual variability in renoprotective effect exists which is mirrored by large individual variability in response in blood pressure, the primary target of Angiotensin Receptor Blockers (ARBs). The response in blood pressure serves as a proxy or surrogate for the longterm effect on cardiovascular and renal outcomes. However, blood pressure is not the only risk marker that is influenced by RAASi. RAASi has a broad spectrum of effects on other renal risk markers including decreasing albuminuria, hemoglobin, uric acid, cholesterol, and increasing potassium [4] [5] [6] [7] [8] . Changes in these renal risk markers have implications for patients' clinical prognosis. Accordingly, RAASi induced changes in all these risk markers could influence the ultimate effect of RAAS blockade on renal outcomes, either positively or negatively.
It has been assumed that the between-patient variability in blood pressure in response to RAAS blockade is paralleled by a similar between-patient variability in other risk markers. If true, measuring multiple risk markers within an individual would not be meaningful as the blood pressure response represents the variability in response to other markers as well. However, several studies show that in a proportion of patients a reduction in blood pressure is not accompanied by a reduction in albuminuria or vice versa [9] [10] [11] . It is unknown, however, whether the response to ARBs in multiple risk markers are paralleled or dissociated from the antihypertensive response within a patient, and whether this explains the inaccuracy of predicting long term renal protection by just looking at the target parameter blood pressure.
We questioned whether a composite of multiple short-term risk marker changes, including on-target and off-target changes, would lead to a more accurate prediction of long-term renal protection. We thus investigated the variability in response in multiple risk markers within an individual and assessed the congruency in response in multiple risk markers within an individual. Secondly, we examined whether inclusion of changes in multiple risk markers of each individual improves prediction of renal outcome. Data of already finished large ARB intervention trials in type 2 diabetic patients with elevated albuminuria (RENAAL, were used for this analysis.
Methods

Data sources and patient population
We used the individual patient data from the RENAAL, IDNT and IRMA-2 trials. The detailed design, rationale, and study outcome for these trials have been previously published [12] [13] [14] . All trials investigated the efficacy of an ARB (losartan in RENAAL and irbesartan in IDNT and IRMA-2) on renal outcomes in subjects with type 2 diabetes and nephropathy. Inclusion criteria for the RENAAL and IDNT trials were similar aside from a few minor differences. Patients with type 2 diabetes, hypertension and age between 30-70 years were eligible for these trials. In RENAAL and IDNT, serum creatinine levels ranged between 1.0 mg/dL and 3.0 mg/dL and all subjects had proteinuria, defined as 24-hour urinary protein excretion of >900 mg in the IDNT trial whereas for RENAAL a urinary albumin to creatinine ratio (UACR) of >300 mg/g or a 24 hour urinary protein excretion >500 mg/day was required. In the IRMA-2 trial, eligible patients had type 2 diabetes and microalbuminuria, defined as urinary albumin excretion between 20 and 200 µg/min, and serum creatinine no more than 1.5 mg/dL in males or 1.1 mg/dL in females. Exclusion criteria for all three trials were type 1 diabetes or non-diabetic renal disease.
Patients randomized to active study treatment received losartan 100 mg/day in RENAAL, irbesartan 300 mg/day in IDNT and irbesartan 150 mg/day or 300 mg/day in IRMA-2 to achieve a blood pressure target of at least 135/85 mmHg. If the blood pressure target was not achieved the dosage of other antihypertensive drugs were increased or additional antihypertensive agents (but not RAASi) were added to achieve the target blood pressure.
The primary endpoint in RENAAL and IDNT used for this analysis was the time to a sustained doubling of baseline serum creatinine or end stage renal disease.
In IDNT, a sustained serum creatinine ≥6.0 mg/dL was used as an additional component in the primary endpoint. All outcomes were adjudicated by an independent blinded endpoint committee using rigorous outcome definitions. Clinical renal endpoints were not recorded in the IRMA-2 trial. All patients signed informed consent before enrollment, and the local Institutional Review Board of each participating center approved the RENAAL, IDNT, and IRMA-2 trial.
Responses in risk markers
This post-hoc analysis focuses on the response in multiple markers including systolic blood pressure (SBP), albuminuria, serum potassium, hemoglobin, total cholesterol, and uric acid. These markers were selected since prior studies have shown that RAASi can affect these risk marker levels when compared to placebo [4] [5] [6] [7] [8] . Uric acid was not included in the analysis for the IDNT and IRMA-2 trials, as it was previously shown that irbesartan does not affect this risk marker [15] . All blood pressure measurements in all trials were taken after a period of at least 5 minutes in sitting position. Three consecutive blood pressure measurements were recorded in the same arm. The mean value of the three systolic and diastolic blood pressure readings was calculated for each study visit. In a subset of patients in the IRMA-2 trial, 24-hour ambulatory blood pressure monitoring was performed as well. Other risk markers (albuminuria, potassium, hemoglobin, cholesterol, uric acid) were measured in a central laboratory in each trial. Albuminuria was measured in first morning void urine collections in RENAAL and IRMA-2 for measurement of the albumin to creatinine ratio. In IDNT, 24-hour urine collections were performed for measurement of the albumin to creatinine ratio. Throughout this chapter albumin to creatinine ratio is designated as albuminuria.
Response in each parameter was defined as the change between the month-6 and baseline value. Responders were defined as patients with a risk marker change in the hypothesized direction. Hence, a 6-month decrease was used to define responders for SBP, albuminuria, hemoglobin, total cholesterol and uric acid, and a 6-month increase was used to define serum potassium responders.
Albuminuria response at month 6 for each patient was calculated as (1 -log ratio of month 6 to baseline albuminuria) multiplied by 100%. On the basis of previous analyses, the month 6 value was chosen because most parameters were measured at month 6, the treatment effects were considered fully present, and few events occurred during the first 6 months [12, 13] .
Integration of responses in multiple risk markers
The effect on all risk markers was combined to calculate an integrated risk marker effect of ARB treatment. To this end, we used a previously described and validated algorithm referred to as the multiple Parameter Risk Efficacy (PRE) score [15, 16] . In short, a multivariable Cox proportional hazards model was used to estimate the coefficients and hazard ratios associated with each risk marker for the first recorded renal event. The regression coefficients for each risk marker were then taken and used as weights for the risk algorithm. The risk algorithm was applied to the risk markers observed in the RENAAL and IDNT trial at baseline and month 6 in order to calculate 3-year renal risk at both time points. The percentage difference in risk between the two time points represents the individual PRE score [15, 17] .
Statistical analysis
Changes in risk marker levels between baseline and month 6 were reported as mean We subsequently assessed whether changes in single risk markers or multiple risk markers improved renal risk prediction. These analyses were conducted in RENAAL and IDNT trials since in the IRMA-2 trial no clinical endpoints were recorded. We used responses in SBP, albuminuria, and individual PRE scores, that represents the integration of 6-month responses in multiple risk markers, in Cox regression analysis. Cox models were adjusted for baseline values of age, gender, eGFR, albuminuria and hemoglobin to take into account differences between patients in renal risk at baseline. We adjusted for these risk markers as they were previously shown to independently predict renal risk [18] . The improvement in predictive performance was assessed by C statistic and relative integrated discrimination improvement (RIDI). The RIDI measures the percentage of increased discrimination when comparing prediction models [19] . A p value of <0.05 was selected as statistically significant. Statistical analysis was conducted with R version 3.0.1 (R Foundation for Statistical Computing, Vienna, Austria).
Results
Baseline characteristics
A total of 531 (71%) of patients assigned to ARB treatment had complete risk marker measurements at baseline and month 6. Baseline characteristics of these patients are presented in Table 1 . The included population did not differ from the overall losartan assigned population. (Supplement Table S1 ).
Between-patient variability in response to losartan
A large variability in responses between individuals in systolic blood pressure (mean 
Within-patient variability in multiple markers in response to losartan
To determine whether responses in systolic blood pressure were paralleled by responses in other risk markers within an individual we assessed responses in all risk markers in the overall population and subsequently in subjects with a reduction in systolic blood pressure. K, potassium; Hb, hemoglobin; chol, cholesterol; UA, uric acid. Table 1 . Baseline characteristics of the included patients.
In mean (SD) unless otherwise indicated. ACR is calculated as median + interquartile range. Baseline measurements for uric acid were not available in the IRMA-2 trial.
The radar plot in Figure 1 shows that the magnitude of responses in all risk markers were similar in the overall population and in the subgroup of patients with a reduction in systolic blood pressure, suggesting that responses are discordant. When responder populations were defined by responses in off-target parameters, the magnitude of responses in the remaining parameters were similar to the overall population (Figure 1) , except for the albuminuria response in uric acid responders.
The number and proportion of patients with a response to losartan in each risk marker are shown in Table 2 . In the overall population a response in SBP was observed in 61% of subjects, albuminuria in 72%, potassium in 66%, hemoglobin in 72%, cholesterol in 61%, and uric acid in 47%. These percentages were not statistically different in sub-group populations defined by a response in SBP or other off-target biomarkers ( Table 2 ). The correlation between responses in individual risk markers within an individual is shown in Number of patients (percentage) with a response in each risk marker. Results are displayed for the total population, and for subsets of responders per risk marker. Chi square tests with a post-hoc Bonferroni correction revealed no statistically significant differences.
Prediction of renal outcome
During a median follow-up of 2. Relative to using changes in SBP to monitor the efficacy of losartan, using the PRE score significantly improved renal risk prediction (RIDI 30.4%; p<0.01; Table 4 ).
The C statistic of the PRE score for the renal outcome was 0.840, significantly higher (p<0.01) than using changes in SBP alone (C statistic: 0.796).
Validation
In order to validate the results, we assessed the variation in response in multiple risk markers to ARBs in two other datasets from completed clinical trials. First, in the IDNT trial, in which patients were treated with the ARB irbesartan, we observed similar response patterns when compared to RENAAL (Supplemental Figure S1 , Table S2 and Table S3 ). As in RENAAL, a response in systolic blood pressure with irbesartan was not associated with other risk markers within individual patients.
Additionally, we observed no correlations between responses within patients in different parameters suggesting that responses in multiple parameters within a patient are discordant. Using the PRE score improved renal risk prediction by 30.5% (p=0.02 compared to using only SBP, Table 4) , with a C statistic of 0.825. Secondly, we validated our results in the IRMA-2 trial in which patients with microalbuminuria were treated with irbesartan (Supplemental Figure S2 , Table S4 and Table S5) .
Results were again similar as in RENAAL with a lack of congruency between changes in multiple risk markers within individuals. In a subset of patients in the IRMA-2 trial systolic blood pressure was measured by 24-hour ambulatory blood pressure monitoring. Again, we observed no correlations in response, similar to the overall population (Supplemental Figure S3 , Table S6 ). 
Discussion
This study shows that the individual variability in renoprotection of RAASi is not only determined by response variation of the target parameter blood pressure, but also by the variation of multiple off-target effects. Since variations in on-target and off-target effects were discordant within individual patients, a composite response score that takes changes in all risk markers into account is needed to optimize the predictive power of treatment-induced short-term risk marker changes for long-term renal outcomes. These results were replicated in two independent datasets.
The variation in response to RAASi has been an area of research interest for several decades [20, 21] . A large variability in the renal response to RAAS intervention has been observed ranging from no effect to a complete arrest of renal function decline [22, 23] . A meta-analysis concluded from trial level data that the degree of blood pressure lowering is associated with the degree of renal protection [24] . It is therefore logical that antihypertensive drugs are titrated to target blood pressure, expecting that this is an accurate indicator of kidney protection. However, ARBs have been shown to affect other renal risk markers than blood pressure, and changes in these risk markers also affect the ultimate renal outcome. In addition to the variable effects of ARBs on multiple risk markers between patients, we also showed that the response in multiple risk markers within individual patients is highly variable. Earlier studies with RAASi already revealed a discordance between blood pressure and albuminuria response to ARBs within individual patients, with both risk markers being independently associated with renal outcome [9] [10] [11] . In line, previous studies also showed that the dose-response for blood pressure is different from the dose-response for albuminuria, confirming that responses to ARBs in these parameters are discordant [25] [26] [27] . Our study builds upon these previous studies and
shows for the first time that blood pressure response is also not congruent with responses in other risk markers. Importantly, none of the other (off-target) risk markers revealed a correlation in response with other risk markers. Therefore, monitoring blood pressure in case of ARB therapy is not sufficient to predict the ultimate renal outcome. Predictive performance of using change in albuminuria or PRE score in a risk prediction model (corrected for baseline age, gender, eGFR, albuminuria and hemoglobin), compared to using SBP. Results are shown for RENAAL and IDNT since clinical renal outcomes were not collected in IRMA-2.
What are potential implications for clinical practice? Blood pressure control is beyond doubt critical to achieve long-term renoprotection. Clinical practice guidelines therefore recommend to measure blood pressure regularly after start of antihypertensive medication to monitor the effectiveness of the instituted therapy.
However, only measuring blood pressure does not capture the potential response in other markers. Because changes in other risk markers are also associated with longterm renal outcome, either contributing or offsetting the effect predicted by blood pressure response alone, our results suggest that it is necessary to monitor the effect on all known risk markers and integrate these effects to be able to accurately predict the ultimate treatment effect of ARBs in individual patients. This could also imply that further dose increase needs to be explored even if the SBP for an individual patient is controlled: the maximal effect on SBP does not necessarily equal the maximal renoprotective effect.
We developed an individual risk algorithm that incorporates drug responses in multiple parameters. In previous studies we showed that this algorithm can be used to predict the effect of ARBs on a population level. In this study we showed that it also accurately predicts the ARB response on an individual level. Our results imply that long-term renoprotection is still possible in the absence of a blood pressure response as long as the composite of the response in other risk markers is favorable for renoprotection. Vice versa, long-term renal damage can occur even if blood pressure is decreased, but changes in other risk markers sum up to a degree of damage that exceeds the renoprotection induced by blood pressure reduction.
The underlying biological mechanisms that govern variation in response within individuals are not yet elucidated but several possible explanations exist. Firstly, there is the possibility of differences in systemic versus renal tissue-specific RAAS activity. In this respect it has been shown that the blood pressure response depends
to a large extent on extra-renal RAAS inhibition whereas it may be possible that the response in other risk markers, such as albuminuria, hemoglobin, potassium, depends on intra-renal RAAS inhibition [28] . Secondly, the susceptibility of an individual in terms of sodium/potassium balance, albuminuria, or blood pressure changes following changes in RAAS activity may be different as a result of differences in genetic make-up, dietary consumption, or their combination [29, 30] .
For example, genetic differences in CYP2C9, the enzyme metabolizing the pro-drug losartan to its active metabolite, may result in variation in drug exposure between individuals [31] . Thirdly, as patients with diabetes and nephropathy use multiple drugs, and concomitant drug use was present in the analyzed clinical trials, drugdrug interaction leading to different responses cannot be excluded. Patients may also respond differently to drugs due to differences in comorbidities, such as renal artery stenosis. Finally, it is possible that the lack of correlation in responses is due to measurement error. However, all risk markers were measured in central laboratories using strict guidelines and criteria and blood pressure was measured according to standardized protocol guidelines. Additionally, the finding that even 24-hour blood pressure response did not produce correlations with responses in other markers in a subset of the IRMA-2 trial makes the possibility of misclassification less likely.
We showed that adding ARB-induced changes to a renal risk model markedly improved renal risk prediction. Much research is focused on developing new biomarker-based models for predicting diabetic disease progression and renal outcomes with generally modest additional value [32] [33] [34] . In this respect it is noteworthy that prediction of renal endpoints markedly improved by considering response to ARBs in readily available clinical parameters. Thus, using the multiple parameter response efficacy (PRE) score is a pragmatic, cheap, and effective tool to improve renal risk prediction.
Our study has limitations. First, the trials included in this study were designed to assess the effects of ARBs on renal disease progression and were not designed to investigate the variability in response. The results of this study are therefore only hypothesis generating. Prospective studies are required to confirm our findings and are currently ongoing (IMPROVE study; Dutch trial register NTR 4439). Although blood pressure was measured according predefined protocol guidelines, 24-hr blood pressure monitoring results were only available in a small subset of patients. In addition, changes in other risk markers were based on changes between two predetermined time points without a confirmatory measurement. We can therefore not exclude that part of the 'response' variability is due to random day-to-day variability and/or measurement variability. Second, the predictions of the PRE score are based on the assumption that the drug effect at six months persists over time. It may be possible however that during prolonged follow-up risk markers of some patients may regress to baseline values. This may have led to an underestimation of the predictive performance of the PRE score.
In conclusion, our study shows that ARBs have variable effects on multiple risk markers (between-patient variability) and these effects vary within patients. An individual risk model that takes variability in treatment response to all known risk markers into account provides a more accurate prediction of who will benefit from ARB therapy than using blood pressure or any other single marker alone. This suggests that in clinical practice all relevant risk markers should be monitored and integrated to fully appreciate the ARB treatment effect on renal outcomes. Further studies are required to prospectively validate these findings.
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Supplemental Supplemental Figure S3 . Variation in SBP response for total and responder population in IRMA-2 subset with 24h SBP measurements. 
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